SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients

Proteomics

Volumn 12, Issue 8, 2012, Pages 1244-1252

  Qin, Shizhen ^a   Zhou, Yong ^a   Lok, Anna S ^b   Tsodikov, Alex ^b   Yan, Xiaowei ^a   Gray, Li ^a   Yuan, Min ^a   Moritz, Robert L ^a   Galas, David ^a   Omenn, Gilbert S ^a,c   Hood, Leroy ^a  

^a INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Biomedicine Fibrosis; Hepatitis C; Liver specific blood biomarkers; Quantitation; Selected reaction monitoring

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT FACTOR H; GLYCOPROTEIN; GLYCOPROTEIN ALPHA 1B; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN ACID LABILE SUBUNIT; PROTEIN C; RETINOL BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEOMICS; SELECTED REACTION MONITORING PROTEOMICS;

ADULT; AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; BLOOD PROTEINS; COMPLEMENT FACTOR H; FEMALE; FIBROSIS; GLYCOPROTEINS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LIVER; LIVER CIRRHOSIS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ORGAN SPECIFICITY; PROTEIN C; PROTEOMICS; RETINOL-BINDING PROTEINS, PLASMA;

HEPATITIS C VIRUS;

EID: 84860851594     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100601     Document Type: Article

References (32)

1. Ghany, M. G., Strader, D. B., Thomas, D. L., Seeff, L. B., Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49, 1335-1374.
2. Regev, A., Berho, M., Jeffers, L. J., Milikowski, C., et al., Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 2002, 97, 2614-2618.
3. Munteanu, M., Ratziu, V., Morra, R., Messous, D., et al., Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J. Gastrointestin. Liver Dis. 2008, 17, 187-191.
4. Everson, G. T., Hoefs, J. C., Seeff, L. B., Bonkovsky, H. L., et al., Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006, 44, 1675-1684.
5. Sheth, S. G., Flamm, S. L., Gordon, F. D., Chopra, S., AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 1998, 93, 44-48.
6. Wai, C. T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., et al., A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38, 518-526.
7. Lok, A. S., Everhart, J. E., Chung, R. T., Kim, H. Y., et al., Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2009, 49, 1828-1837.
8. Picotti, P., Bodenmiller, B., Mueller, L. N., Domon, B., Aebersold, R., Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009, 138, 795-806.
9. Picotti, P., Rinner, O., Stallmach, R., Dautel, F., et al., High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat. Methods 2010, 7, 43-46.
10. Ghany, M. G., Kim, H. Y., Stoddard, A., Wright, E. C., et al., Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology 2011, 54, 1527-1537.
11. Lin, B., Madan, A., Yoon, J. G., Fang, X., et al., Massively parallel signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI and SOX4 in human glioblastoma. PLoS One 2010, 5, e10210.
12. Ge, X., Yamamoto, S., Tsutsumi, S., Midorikawa, Y., et al., Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005, 86, 127-141.
13. Roth, R. B., Hevezi, P., Lee, J., Willhite, D., et al., Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 2006, 7, 67-80.
14. Su, A. I., Wiltshire, T., Batalov, S., Lapp, H., et al., A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. USA 2004, 101, 6062-6067.
15. Lange, V., Picotti, P., Domon, B., Aebersold, R., Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008, 4, 222.
16. Deutsch, E. W., Lam, H., Aebersold, R., PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows. EMBO Rep. 2008, 9, 429-434.
17. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., et al., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26, 966-968.
18. Gentleman, R., Irizarry, R. A., Carey, V. J., Dudoit, S., Huber W, Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Springer, New York 2005.
19. Troyanskaya, O., Cantor, M., Sherlock, G., Brown, P., et al., Missing value estimation methods for DNA microarrays. Bioinformatics 2001, 17, 520-525.
20. Zou, H., Hastie, T., Regularization and variable selection via the elastic net. J. Roy. Stat. Soc. B 2005, 67, 301-320.
21. Rai, A. J., Gelfand, C. A., Haywood, B. C., Warunek, D. J., et al., HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5, 3262-3277.
22. Gahne, B., Juneja, R. K., Stratil, A., Genetic polymorphism of human plasma alpha 1B-glycoprotein: phenotyping by immunoblotting or by a simple method of 2-D electrophoresis. Hum. Genet. 1987, 76, 111-115.
23. Polanski, M., Anderson, N. L., A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007, 1, 1-48.
24. Farrah, T., Deutsch, E. W., Omenn, G. S., Campbell, D. S., et al., A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol. Cell. Proteomics 2011, 10, M110.006353.
25. Grigorescu, M., Noninvasive biochemical markers of liver fibrosis. J. Gastrointestin. Liver Dis. 2006, 15, 149-159.
26. Afdhal, N. H., Nunes, D., Evaluation of liver fibrosis: a concise review. Am. J. Gastroenterol. 2004, 99, 1160-1174.
27. Ray S, T. D., Hepatitis C, Churchill, Livingston, Elsevier., Philadelphia, PA 2009.
28. Kloczko, J., Mian, M., Wojtukiewicz, M. Z., Babiuch, L., et al., Plasma protein C as a marker of hepatocellular damage in alcoholic liver disease. Haemostasis 1992, 22, 340-344.
29. Romanowska, A., Lebensztejn, D. M., Skiba, E., Tarasow, E., Kaczmarski, M., Retinol binding protein-4 as a serum biomarker of intrahepatic lipid content in obese children-preliminary report. Acta Biochim. Pol. 2011, 58, 35-38.
30. Cengiz, C., Ardicoglu, Y., Bulut, S., Boyacioglu, S., Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis? Eur. J. Gastroenterol. Hepatol. 2010, 22, 813-819.
31. Fan, R., Vermesh, O., Srivastava, A., Yen, B. K., et al., Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nat. Biotechnol. 2008, 26, 1373-1378.
32. Hood, L., Friend, S. H., Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat. Rev. Clin. Oncol. 2011, 8, 184-187.